Skip to main content
OpenTrials

Clinical trial condition

Thyroid cancer, Hurthle cell

Explore clinical trials studying Thyroid cancer, Hurthle cell. Study availability and eligibility vary by location and protocol.

10 public trials 1 recruiting study
Refine in advanced search Browse all conditions

Thyroid cancer, Hurthle cell trial results

Completed

Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)

NCT02973997

Conditions
Adenocarcinoma, Adenocarcinoma, Follicular, Adenocarcinoma, Papillary, +38 more
Locations
  • Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center Torrance, California, United States
  • University of Colorado Hospital Aurora, Colorado, United States
  • Massachusetts General Hospital Cancer Center Boston, Massachusetts, United States
  • University of Michigan Comprehensive Cancer Center Ann Arbor, Michigan, United States
View Trial Details
Completed

Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer

NCT01208051

Conditions
Adenocarcinoma, Adenocarcinoma, Follicular, Adenocarcinoma, Papillary, +17 more
Locations
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • USC / Norris Comprehensive Cancer Center Los Angeles, California, United States
  • University of California Davis Comprehensive Cancer Center P2C Sacramento, California, United States
  • University of California Davis Comprehensive Cancer Center Sacramento, California, United States
View all 33 locations
View Trial Details
Completed

Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer

NCT01811212

Conditions
Adenocarcinoma, Adenocarcinoma, Follicular, Adenocarcinoma, Papillary, +28 more
Locations
  • MedStar Georgetown University Hospital Washington D.C., District of Columbia, United States
  • Mayo Clinic in Florida Jacksonville, Florida, United States
  • University of Chicago Comprehensive Cancer Center Chicago, Illinois, United States
  • Massachusetts General Hospital Cancer Center Boston, Massachusetts, United States
View Trial Details
Active, Not Recruiting

IoN- Is Ablative Radio-iodine Necessary for Low Risk Differentiated Thyroid Cancer Patients

NCT01398085

Conditions
Adenocarcinoma, Adenocarcinoma, Follicular, Adenocarcinoma, Papillary, +13 more
Locations
  • Belfast Health and Social Care Trust Belfast, United Kingdom
  • University Hospitals Birmingham NHS Foundation Trust Birmingham, United Kingdom
  • University Hospitals Sussex NHS Foundation Trust Brighton, United Kingdom
  • University Hospital Bristol NHS Foundation Trust Bristol, United Kingdom
View all 36 locations
View Trial Details
Active, Not Recruiting

Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer

NCT02143726

Conditions
Refractory Hurthle Cell Thyroid Cancer, Thyroid cancer, Hurthle cell
Locations
  • Mayo Clinic in Florida Jacksonville, Florida, United States
  • Northwestern University Chicago, Illinois, United States
  • Siouxland Regional Cancer Center Sioux City, Iowa, United States
  • University of Michigan Comprehensive Cancer Center Ann Arbor, Michigan, United States
View all 21 locations
View Trial Details
Active, Not Recruiting

PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer

NCT04544111

Conditions
Adenocarcinoma, Adenocarcinoma, Follicular, Adenocarcinoma, Papillary, +22 more
Locations
  • Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) Basking Ridge, New Jersey, United States
  • Memorial Sloan Kettering Monmouth (Limited protocol activities) Middletown, New Jersey, United States
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities) Montvale, New Jersey, United States
  • Memorial Sloan Kettering Cancer Center @ Suffolk - Commack (Limited Protocol Activities) Commack, New York, United States
View Trial Details

Related conditions